Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

PDMR Dealing


Posted on: 21 Aug 17

LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 122.5 pence per Ordinary Share.  Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company’s issued share capital.

The notification of dealing form can be found below.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officerinfo@veronapharma.com
  
N+1 Singer (Nominated Adviser and UK Broker)Tel: +44 (0)20 7496 3000
Aubrey Powell / James White 
  
FTI Consulting (UK Media and Investor enquiries)Tel: +44 (0)20 3727 1000
Simon Conway /  Natalie Garland-Collinsveronapharma@fticonsulting.com
  
ICR, Inc. (US Media and Investor enquiries) 
Darcie RobinsonTel: +1 203-682-8379
Darcie.Robinson@icrinc.com
Stephanie CarringtonTel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


1Details of the person discharging managerial responsibilities/person closely associated
a)NameDavid Ebsworth
2Reason for the notification
a)Position/statusNon-Executive Chairman
b)Initial notification/AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerona Pharma plc
b)LEI213800EVI6O6J3TIAL06
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary Shares of 5 pence each
Identification codeGB00BYW2KH80
b)Nature of the transactionDavid Ebsworth purchased 8,130 Ordinary Shares
c)Price(s) and volume(s)Price(s)Volume(s)
122.5 pence per Ordinary Share8,130 Ordinary Shares
 
d)Aggregated informationN/A
-  Aggregated volume
-  Price
 
e)Date of the transaction17 August 2017
f)Place of the transactionLondon Stock Exchange, AIM


GlobeNewswire
globenewswire.com

Last updated on: 22/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.